Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Acquisition costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — acquisition costs?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — acquisition costs of $0 in Q2 2026.
- What does avkare — acquisition costs mean?
- Includes non-recurring expenses directly related to the acquisition, transaction, and integration of new businesses into the AvKARE segment. Investors monitor this to distinguish between core operational performance and the one-time costs associated with inorganic growth strategies.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — acquisition costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude